Genentech
Top View
- Roche Vows to Keep Genentech Culture
- Vertex Pharmaceuticals Incorporated
- A First-In-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) with Selected Advanced Solid Tumors (ENGAGE-1)
- 1996 Annual-Report.Pdf
- Amgen and Genentech Settle Patent Dispute
- Amgen and Genentech Sign License Agreements for Antibody Patents
- Integrating Peripheral Biomarker Analyses From
- Vertex Pharmaceuticals Incorporated
- Prescriber Service Form SUBMIT ONLY REQUESTED DOCUMENTS Required Field (*)
- Genentech and Biogen Idec Have Filed for a Re-Hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
- Tanox Is a Biotechnology Company Specializing in the Discovery and Development of Biotherapeutics Utilizing Monoclonal Antibody Technology
- 10-17-09 Rituxan RA CRL Press Release FINAL
- The ASCO Post Editor Conflict of Interest Disclosures
- Faculty Disclosures
- Genentech, Inc
- ALPINE KEY ELIGIBILITY CRITERIA • Bruton Tyrosine Kinase (BTK) Plays a Critical Role in B‑Cell Receptor Signaling, Which Mediates B‑Cell Table 1
- TECENTRIQ Prescribing Information
- Option to Develop Exelixis Compound Exercised by Genentech